Frontier Pharma: Prostate Cancer Identifying and Commercializing First-inClass Innovation
Single User License - $6995 Site User License - $13990 Corporate User License - $20985 Publication Date - Nov 2014 Pages - 91 To know more details, email to debora@reportstack.com
Contact: debora@reportstack.com Reportstack Market Research
Summary ď ś Exceptionally Large and Innovative Pipeline The prostate cancer pipeline is among the largest in the pharmaceutical industry with 484 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations in this pipeline is exceptional; The Research analysis identified 174 first-in-class programs in the prostate cancer pipeline, acting on 122 first-in-class molecular targets. This accounts for some 36% of all products with a disclosed molecular target and is reflective of the high degree of innovation in this indication.
Contact: debora@reportstack.com Reportstack Market Research
Summary(Contd‌) ď ś Alignment of First-in-Class Molecular Target with Disease Causation One of the key trends in oncology and in prostate cancer in particular over the last decade is the clinical and commercial impact of targeted therapies designed to target proteins in signaling pathways that are strongly associated with disease progression. By aligning the molecular targets for therapeutic intervention with disease causation and/or propagation, these therapies limit the systemic cytotoxic effects whilst inhibiting tumor-promoting signaling pathways. Such strategies thereby typically achieve superior efficacy and safety profiles.
Contact: debora@reportstack.com Reportstack Market Research
Scope - A brief introduction to prostate cancer, including symptoms, pathophysiology, and overview of pharmacotherapy and treatment algorithms. - The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline. - Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target. - Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets. - Assessment of the licensing and co-development deal landscape for prostate cancer therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products. Contact: debora@reportstack.com
Key Benefits - Understanding of the focal shifts in molecular targets in the prostate cancer pipeline. - Understanding of the distribution of pipeline programs by phase of development, molecule type and molecular target. - Access a scientific and clinical analysis of first-in-class developmental programs for prostate cancer, benchmarked against non-first-in-class targets. - Access a list of the first-in-class therapies potentially open to deal-making opportunities"
Contact: debora@reportstack.com Reportstack Market Research
If you are interested...
Contact : Debora White Email: debora@reportstack.com Ph:+1-888-789-6604 http://www.reportstack.com
Contact: debora@reportstack.com Reportstack Market Research